Bristol-Myers Squibb announces pooled five-year survival results for Opdivo in NSCLC
Bristol-Myers Squibb announced long-term pooled efficacy and safety results from the Phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced NSCLC. At five years, patients treated with Opdivo (nivolumab) continued to experience long-term OS benefit. September 10, 2019